Showing results (71-80 of 112) with videos related to
Sort By:
Pageof 12
Journal of Thrombosis and Haemostasis : JTH|March 27, 2013
Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the proteinE K Waters, R M Genga, H A Thomson, et al.Thrombosis and Haemostasis|June 1, 2002
Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeysK McCarthy, P Stewart, J Sigman, et al.Critical Reviews in Immunology|January 1, 1997
Regulation of the inflammatory response in animal models of multiple sclerosis by interleukin-12J P Leonard, K E Waldburger, R G Schaub, et al.Journal of Biomedical Materials Research|October 1, 1994
Healing of large segmental defects in rat femurs is aided by RhBMP-2 in PLGA matrixS C Lee, M Shea, M A Battle, et al.Thrombosis and Haemostasis|August 28, 2007
The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding timeMichael Wadanoli, Dianne Sako, Gray D Shaw, et al.Thrombosis and Haemostasis|January 1, 1995
Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dogJ C Keith, T J Ferranti, B Misra, et al.The American Journal of Physiology|September 1, 1987
Use of ultrasound for noninvasive study of blood vessel responsivenessG J Stewart, M C Ziskin, R G Schaub, et al.Transfusion|January 15, 2010
The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivoFlorian B Mayr, Paul Knöbl, Bernd Jilma, et al.Blood|March 11, 2011
Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitorEmily K Waters, Ryan M Genga, Michael C Schwartz, et al.The Journal of Experimental Medicine|June 1, 1993
Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune responseJ P Sypek, C L Chung, S E Mayor, et al.Pageof 12